Clinical trials: Levodopa
Parkinson's Disease (PD)
Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide
The purpose of this study is to determine the effect of three single oral doses of nebicapone (50 mg, 100 mg and 200 mg) on the levodopa pharmacokinetics when administered in combination with a single-dose of controlled release…
- Trial name
- NCT02778594
- Testing
- BIA 3-202, levodopa 100 mg / benserazide 25 mg
- Where
- Portugal
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Depression, HIV Infections
PET Imaging of the Dopaminergic and Serotonergic Systems in Treated HIV Positive Subjects
Background: Human immunodeficiency virus (HIV) infection is a serious disease with no cure. Some people with HIV have depression and other mood problems. They can have problems with thinking and memory.
- Conditions
- Depression, HIV Infections, HIV-Associated Cognitive Motor Complex
- Trial name
- NCT03581305
- Testing
- 18F-FDOPA, 11C-DASB
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- National Institutes of Health Clinical Center (CC)
Parkinson's Disease (PD)
Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Immediate-release Levodopa/Benserazide
To investigate the effect of three single oral doses of BIA 9-1067 (25 mg, 50 mg and 100 mg) on the levodopa pharmacokinetics when administered in combination with a single-dose of immediate-release levodopa/benserazide 100/25 mg…
- Trial name
- NCT02169895
- Testing
- BIA 9-1067, Prolopa®
- Where
- Canada
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Fasted State
Pharmacokinetic Study With Levodopa-carbidopa Fixed-dose Products in Healthy Subjects After Oral Administration
The study is carried-out to describe and compare the plasma pharmacokinetics of levodopa and carbidopa after oral single-dose administration of 100 mg levodopa plus 25 mg carbidopa by means two fixed combination products (test…
- Trial name
- LCD18K (NCT02116465)
- Testing
- Levodopa Carbidopa immediate release tablets
- Where
- Bulgaria
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Desitin Arzneimittel GmbH
Parkinson Disease, Medication
Behavioural Profiling of Disease-related Cognitive and Motor Impairment in PD
In this project, patients with Parkinson's Disease (PD) will be characterized by measuring cognitive and motor function and relation to effect of Levodopa.
- Conditions
- Parkinson Disease, Medication, UPDRS, Motor Function
- Trial name
- NCT06275633
- Testing
- Levodopa
- Where
- Denmark
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- University Hospital Bispebjerg and Frederiksberg
Healthy
Bioequivalence Study of Entacapone,Levodopa and Carbidopa Tablets in Healthy Chinese Subjects
In this trial, 32 healthy subjects are planned to be enrolled in fasting and 36 healthy subjects are planned to be enrolled in postprandial, and the fasting and postprandial trials will be randomized separately.
- Trial name
- NCT05976737
- Testing
- Test (T) Entacapone,Levodopa and Carbidopa Tablets (II), Reference (R) Entacapone,Levodopa and Carbidopa Tablets (II)
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- The Affiliated Hospital of Qingdao University
Healthy
Bioequivalence Study of Carbidopa/Levodopa/Entacapone Combination vs. Carbidopa/Levodopa Combination Plus Entacapone in Healthy Volunteers
The purpose of this study is to assess the safety and bioequivalence of a single oral dose of carbidopa+levodopa+entacapone combination versus a single oral dose of carbidopa+levodopa combination plus a single oral dose of…
- Trial name
- NCT00415740
- Testing
- ELC200 (carbidopa+levodopa+entacapone)
- Where
- Germany
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Novartis
Retinal Diseases
Effect of Levodopa on Human Multifocal Electroretinogram
It is known that dopamine is a functional neuromodulator at several levels of the visual system. Dopamine seems to be involved in the organization of the ganglion cell and the bipolar cell receptive fields and modulation of…
- Trial name
- NCT00812760
- Testing
- levodopa
- Where
- Austria
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Parkinson's Disease
Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Carbidopa (100/25 mg)
The purpose of this study is to investigate the tolerability, pharmacokinetic profile of BIA 3-202 and its metabolites, and the pharmacokinetic and pharmacodynamic interaction between 4 different single doses of BIA 3-202 (50 mg…
- Trial name
- NCT02763839
- Testing
- BIA 3-202, Sinemet 25/100
- Where
- Portugal
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Visual Attention in Parkinson's Disease
Visual Selective Attention in Parkinson's Disease
Parkinson's disease (PD), which is generally considered to be a motor disorder, is now known to be accompanied in many instances by a variety of cognitive defects.
- Trial name
- VSA-PD (NCT01135407)
- Testing
- Recording during computerized tests
- Where
- France
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University Hospital, Grenoble
Parkinson Disease
Action Regulation Behavioral
Parkinson's disease (PD) is a neurodegenerative disorder involving a part of the brain that is responsible for motor control, which not only results in changes or disruptions in movement, but also cognitive dysfunctions.
- Trial name
- NCT06489483
- Testing
- Action Regulation Movement Task
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Parkinson's Disease
A Single Period Investigation to Assess the Tolerability of Healthy Subjects to Oral Sinemet® (Levodopa/Carbidopa)
A Single Period Investigation to Assess the Tolerability of Healthy Subjects to Oral Sinemet® (Levodopa/Carbidopa) Doses Administered Using a Divided Dose Approach
- Trial name
- NCT02486432
- Testing
- Levodopa/Carbidopa (Sinemet)
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- NeuroDerm Ltd.
Parkinson's Disease
Safety, Tolerability and Pharmacokinetic Profile of Levodopa Administered With Continuous Administration of ND0611
The study hypothesis is that continuous ND0611 increases the bioavailability of levodopa and therefore the levodopa area-under-the-concentration-curve values, half-life, and trough concentrations The study will help determining…
- Trial name
- NCT01103011
- Testing
- ND0611
- Where
- Israel
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- NeuroDerm Ltd.
Late Life Depression, Cognitive Decline
Dopaminergic Dysfunction in Late-Life Depression
Late-Life Depression (LLD), or depression in older adults, often presents with motivational deficits, deficits in performance in cognitive domains including processing speed and executive dysfunction, and mobility impairments.
- Conditions
- Late Life Depression, Cognitive Decline, Depressive Disorder, Treatment-Resistant, Levodopa
- Trial name
- D3 (NCT04469959)
- Testing
- L-Dopa
- Where
- 2 sites in United States
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Parkinson's Disease
Study of Subcutaneous Continuous Administration of Levodopa/Carbidopa Solution (ND0612) in Healthy Volunteers
It will be a single dose, single-center, randomized, double-blind, placebo-controlled dose escalation study of SC continuously-delivered LD/CD solution (ND-0612) for 24 hours in healthy volunteers. Objectives are to determine: 1.
- Trial name
- NCT01486628
- Testing
- ND0612
- Where
- Israel
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- NeuroDerm Ltd.
Parkinson's Disease
Pharmacokinetic Study in Healthy Males
The purpose of this study is to investigate the pharmacokinetics of levodopa, carbidopa, 3-OMD and ODM-104 after repeated doses of 3 levodopa formulations given in combination with carbidopa and ODM-104.
- Trial name
- NOCOF (NCT02312232)
- Testing
- levodopa, carbidopa, ODM-104
- Where
- Finland
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Orion Corporation, Orion Pharma
Parkinson Disease
Study of Dysarthria, and the Appearance of Non-dopaminergic Signs in Idiopathic PARKinson's Disease
Pilot study: Longitudinal follow up of the PRODY-GI cohort for parkinson's disease (PD) Observational study of upper and lower axial symptoms' occurence in 30 PD patients in on and off drug conditions, 30 aged matched control…
- Trial name
- Prodygi-II (NCT03517059)
- Where
- France
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- University Hospital, Lille
Parkinson Disease
Comparative Bioavailability Study of Carbidopa/Levodopa Extended-Release Tablets Under Fasting and Fed Conditions
It is an open-label, balanced, randomized, five-treatment, five-period, five-sequence, multiple oral dose, crossover comparative bioavailability study of different strengths of carbidopa/levodopa extended-release tablets with…
- Trial name
- NCT05128175
- Testing
- WD-1603 Carbidopa-Levodopa Extended-Release Tablets
- Where
- India
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Shanghai WD Pharmaceutical Co., Ltd.
Parkinson's Disease (PD)
Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide
To investigate the effect of three single oral doses of BIA 9-1067 (25 mg, 50 mg and 100 mg) on the levodopa pharmacokinetics when administered in combination with a single-dose of controlled-release levodopa 100 mg/benserazide…
- Trial name
- NCT02169466
- Testing
- BIA 9-1067, Madopar® HBS
- Where
- Portugal
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Healthy Volunteers
Fasting Comparative Bioavailability of Two Tablet Formulations of Levodopa /Benserazide in Healthy Volunteers
A group of 24 healthy volunteers receive one tablet of an association of levodopa 200 mg and benserazide 50 mg corresponding to two drug products: a test formulation (Evoser ®; Phoenix S.A.I.C.
- Trial name
- PHOE10903 (NCT01327261)
- Testing
- Levodopa + benserazide
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Buenos Aires